dict.md logo
Results for O in English, page 50
ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R0 RESECTION (WITH OR WITHOUT NEOADJUVANT THERAPY) WITH NO EVIDENCE OF DISEASE RECURRENCE, PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONS
ONCOLOGY; DISEASE STATUS; GASTRIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R1 OR R2 RESECTION (WITH OR WITHOUT NEOADJUVANT THERAPY) WITH NO EVIDENCE OF DISEASE PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATIO
ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-T2 AND N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO
ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T3-4 AND/OR N1-3, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH
ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION
ONCOLOGY; DISEASE STATUS; HEAD AND NECK CANCER, LIMITED TO CANCERS OF ORAL CAVITY, PHARYNX AND LARYNX WITH SQUAMOUS CELL AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJE
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, UNDER EVALUATION, PRE-SURGICAL OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRA
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJ
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE I OR STAGE IIA-IIB; OR T3, N1, M0; AND ER AND/OR PR POSITIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECU
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE I, OR STAGE IIA-IIB; OR T3, N1, M0; AND ER AND PR NEGATIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURR
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE IIIA-IIIB; AND NOT T3, N1, M0; AND ER AND PR NEGATIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE,
ONCOLOGY; DISEASE STATUS; INVASIVE FEMALE BREAST CANCER (DOES NOT INCLUDE DUCTAL CARCINOMA IN SITU); ADENOCARCINOMA AS PREDOMINANT CELL TYPE; STAGE IIIA-IIIB; AND NOT T3, N1, M0; AND ER AND/OR PR POSITIVE; WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURREN
ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; SMOLDERING, STAGE I (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; LIMITED TO MULTIPLE MYELOMA, SYSTEMIC DISEASE; STAGE II OR HIGHER (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE I (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED
ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE II (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED
ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE INITIALLY ESTABLISHED AS STAGE III A (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPRO
ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; LIMITED TO NON-SMALL CELL LUNG CANCER; STAGE III B- IV AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENT OF DISEASE INITIALLY ESTABLISHED AS LIMITED WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PRO
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE TO THERAPY, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, ANY CELLULAR CLASSIFICATION; STAGE III, IV, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; DIAGNOSTIC EVALUATION, STAGE NOT DETERMINED, EVALUATION OF POSSIBLE RELAPSE OR NON-RESPONSE
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; RELAPSED/REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE I, II AT DIAGNOSIS, NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMON
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, LIMITED TO FOLLICULAR LYMPHOMA, MANTLE CELL LYMPHOMA, DIFFUSE LARGE B-CELL LYMPHOMA, SMALL LYMPHOCYTIC LYMPHOMA; STAGE III, IV NOT RELAPSED, NOT REFRACTORY (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PRO
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA, TRANSFORMED FROM ORIGINAL CELLULAR DIAGNOSIS TO A SECOND CELLULAR CLASSIFICATION (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; NON-HODGKIN'S LYMPHOMA; TRANSFORMED FROM FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; EVIDENCE OF DISEASE PROGRESSION, OR RECURRENCE, AND/OR PLATINUM RESISTANCE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE IA-B (GRADE 1) WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE IA-B (GRADE 2-3); OR STAGE IC (ALL GRADES); OR STAGE II; WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRAT
ONCOLOGY; DISEASE STATUS; OVARIAN CANCER, LIMITED TO EPITHELIAL CANCER; PATHOLOGIC STAGE III-IV; WITHOUT EVIDENCE OF PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; POST R0 RESECTION WITHOUT EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; POST R1 OR R2 RESECTION WITH NO EVIDENCE OF DISEASE PROGRESSION, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PANCREATIC CANCER, LIMITED TO ADENOCARCINOMA; UNRESECTABLE AT DIAGNOSIS, M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T1-T2C AND GLEASON 2-7 AND PSA < OR EQUAL TO 20 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T2 OR T3A GLEASON 8-10 OR PSA > 20 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA AS PREDOMINANT CELL TYPE; T3B-T4, ANY N; ANY T, N1 AT DIAGNOSIS WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE, OR METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; AFTER INITIAL TREATMENT WITH RISING PSA OR FAILURE OF PSA DECLINE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; CASTRATE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-REFRACTORY/ANDROGEN-INDEPENDENT (E.G., RISING PSA ON ANTI-ANDROGEN THERAPY OR POST-ORCHIECTOMY); CLINICAL METASTASES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; HORMONE-RESPONSIVE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; PROSTATE CANCER, LIMITED TO ADENOCARCINOMA; NON-CASTRATE, INCOMPLETELY CASTRATE; CLINICAL METASTASES OR M1 AT DIAGNOSIS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-2, N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURREN
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T1-3, N1-2, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURR
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T3, N0, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRENCE
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE INITIALLY ESTABLISHED AS T4, ANY N, M0 (PRIOR TO NEO-ADJUVANT THERAPY, IF ANY) WITH NO EVIDENCE OF DISEASE PROGRESSION, RECURRE
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; RECTAL CANCER, LIMITED TO INVASIVE CANCER, ADENOCARCINOMA AS PREDOMINANT CELL TYPE; M1 AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL CELL; EXTENSIVE STAGE AT DIAGNOSIS, METASTATIC, LOCALLY RECURRENT, OR PROGRESSIVE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; DISEASE STATUS; SMALL CELL LUNG CANCER, LIMITED TO SMALL CELL AND COMBINED SMALL CELL/NON-SMALL; EXTENT OF DISEASE UNKNOWN, STAGING IN PROGRESS, OR NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT ADHERES TO GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES AS A RESULT OF PATIENT ENROLLMENT IN AN INSTITUTIONAL REVIEW BOARD APPROVED CLINICAL TRIAL (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE PATIENT, AFTER BEING OFFERED TREATMENT CONSISTENT WITH GUIDELINES, HAS OPTED FOR ALTERNATIVE TREATMENT OR MANAGEMENT, INCLUDING NO TREATMENT (FOR USE IN A MEDICARE-APPROVED DEMO
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES BECAUSE THE TREATING PHYSICIAN DISAGREES WITH GUIDELINE RECOMMENDATIONS (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES FOR OTHER REASON(S) NOT LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; MANAGEMENT DIFFERS FROM GUIDELINES FOR REASON(S) ASSOCIATED WITH PATIENT COMORBID ILLNESS OR PERFORMANCE STATUS NOT FACTORED INTO GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRACTICE GUIDELINES; PATIENT'S CONDITION NOT ADDRESSED BY AVAILABLE GUIDELINES (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRIMARY FOCUS OF VISIT; EXPECTANT MANAGEMENT OF PATIENT WITH EVIDENCE OF CANCER FOR WHOM NO CANCER DIRECTED THERAPY IS BEING ADMINISTERED OR ARRANGED AT PRESENT; CANCER DIRECTED THERAPY MIGHT BE CONSIDERED IN THE FUTURE (FOR USE IN A MEDICARE-AP
ONCOLOGY; PRIMARY FOCUS OF VISIT; OTHER, UNSPECIFIED SERVICE NOT OTHERWISE LISTED (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
ONCOLOGY; PRIMARY FOCUS OF VISIT; SUPERVISING, COORDINATING OR MANAGING CARE OF PATIENT WITH TERMINAL CANCER OR FOR WHOM OTHER MEDICAL ILLNESS PREVENTS FURTHER CANCER TREATMENT; INCLUDES SYMPTOM MANAGEMENT, END-OF-LIFE CARE PLANNING, MANAGEMENT OF PALLIAT
ONCOLOGY; PRIMARY FOCUS OF VISIT; SURVEILLANCE FOR DISEASE RECURRENCE FOR PATIENT WHO HAS COMPLETED DEFINITIVE CANCER-DIRECTED THERAPY AND CURRENTLY LACKS EVIDENCE OF RECURRENT DISEASE; CANCER DIRECTED THERAPY MIGHT BE CONSIDERED IN THE FUTURE (FOR USE IN
ONCOLOGY; PRIMARY FOCUS OF VISIT; TREATMENT DECISION-MAKING AFTER DISEASE IS STAGED OR RESTAGED, DISCUSSION OF TREATMENT OPTIONS, SUPERVISING/COORDINATING ACTIVE CANCER DIRECTED THERAPY OR MANAGING CONSEQUENCES OF CANCER DIRECTED THERAPY (FOR USE IN A MED
ONCOLOGY; PRIMARY FOCUS OF VISIT; WORK-UP, EVALUATION, OR STAGING AT THE TIME OF CANCER DIAGNOSIS OR RECURRENCE (FOR USE IN A MEDICARE-APPROVED DEMONSTRATION PROJECT)
oncology/hematology, pediatric
oncology/neurology, pediatric
Oncolym
Oncolysin B
Oncolysis
Oncolytic
Oncolytic Ad5-Delta 24RGD
Oncolytic Adenovirus Ad5-Delta 24RGD
oncolytic adenovirus encoding GM-CSF
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
ONCOLYTIC VIROTHER
Oncolytic Virotherapies
Oncolytic Virotherapy
Oncolytic Virus
ONCOLYTIC VIRUS THER
Oncolytic Virus Therapies
Oncolytic Virus Therapy
Oncolytic Viruses
Oncomegas
Oncomegas australiensis
Oncomegas sp. PDO-2006
Oncomegoides
Oncomegoides celatus
Oncomelania
Oncomelania hupensis
Oncomelania hupensis Gredler,1881
Oncomelania minima
Oncomelania minima P. Bartsch, 1936
Oncomerella
Oncomerella venosa
Oncomerella venosa (Lewis, 1895)
ONCOMETER, PLASMA, FOR CLINICAL USE
Oncometers
Oncometopia
Oncometopia nigricans
Oncometopia orbona
oncoming
oncoming traffic
oncoming train
oncomodulin
oncomodulin 1
oncomodulin 2
oncomodulin protein, human
oncomodulin protein, mouse
oncomodulin protein, rat
Onconase
Onconase/TAM
Onconase/Tamoxifen
Onconase/TMX
Onconeural Ventral Antigen-1
ONCONEURONAL ANTIGEN MA2
Onconida
Onconida alaini
Onconida tropis
Oncopeltus
Oncopeltus fasciatus
Oncophage
Oncophanes
Oncophanes pronotalis
Oncophanes sp.
Oncophanes sp. 1 AZR-2008
Oncophorus
Oncophorus virens
Oncophorus wahlenbergii
Oncopodidae
Oncopodoidea
Oncopodura
Oncopodura crassicornis
Oncopoduridae
oncoprecipitin A
Oncoprotein
Oncoprotein 18
oncoprotein 18 protein, human
oncoprotein 18, mouse
oncoprotein 18, rat
oncoprotein CLTCL-ALK
oncoprotein DEK, human
oncoprotein E2A-Pbx1
oncoprotein E2A-Pbx1, isoform a
oncoprotein E2A-Pbx1, isoform b
oncoprotein induced transcript 3
oncoprotein kinase Tpl2, human
ONCOPROTEIN MDM2
oncoprotein p21
oncoprotein p28GANK, mouse
Oncoprotein p53
ONCOPROTEIN-INDUCED TRANSCRIPT 3, MOUSE, HOMOLOG OF
Oncoproteins
oncopterin
Oncopus
Oncopus malayanus
Oncopus malayanus (Schwendinger & Martens, 2004)
Oncopus sp. GG-1997
Oncorhynchus
Oncorhynchus apache
Oncorhynchus apache (Miller, 1972)
Oncorhynchus clarki
Oncorhynchus clarkii
Oncorhynchus clarkii (Richardson, 1836)
Oncorhynchus gilae
Oncorhynchus gilae (Miller, 1950)
Oncorhynchus gorbuscha
Oncorhynchus gorbuscha (Walbaum, 1792)
Oncorhynchus keta
Oncorhynchus keta (Walbaum, 1792)
Oncorhynchus kisutch
Oncorhynchus kisutch (Walbaum, 1792)
Oncorhynchus masou
Oncorhynchus masou (Brevoort, 1856)
Oncorhynchus masou herpes virus
Oncorhynchus mykiss
Oncorhynchus mykiss (Walbaum, 1792)
Oncorhynchus mykiss Ab
Oncorhynchus mykiss Ab.IgE
Oncorhynchus mykiss Ab.IgE:ACnc:Pt:Ser:Qn
Oncorhynchus mykiss Ab.IgE.RAST class
Oncorhynchus mykiss Ab.IgE.RAST class:ACnc:Pt:Ser:Ord
Oncorhynchus mykiss Ab.IgG
Oncorhynchus mykiss Ab.IgG:ACnc:Pt:Ser:Qn
Oncorhynchus mykiss Ab.IgG.RAST class
Oncorhynchus mykiss Ab.IgG.RAST class:ACnc:Pt:Ser:Ord
Oncorhynchus mykiss Ab.IgG4
Oncorhynchus mykiss Ab.IgG4:MCnc:Pt:Ser:Qn
Oncorhynchus mykiss Antibody.IgG4
Oncorhynchus mykiss Antibody.IgG4:Mass Concentration:Point in time:Serum:Quantitative
Oncorhynchus mykiss Antibody.immunoglobulin E
Oncorhynchus mykiss Antibody.immunoglobulin E:Arbitrary Concentration:Point in time:Serum:Quantitative
Oncorhynchus mykiss Antibody.immunoglobulin E.RAST class
Oncorhynchus mykiss Antibody.immunoglobulin E.RAST class:Arbitrary Concentration:Point in time:Serum:Ordinal
Oncorhynchus mykiss Antibody.immunoglobulin G
Oncorhynchus mykiss Antibody.immunoglobulin G:Arbitrary Concentration:Point in time:Serum:Quantitative
Oncorhynchus mykiss Antibody.immunoglobulin G.RAST class
Oncorhynchus mykiss Antibody.immunoglobulin G.RAST class:Arbitrary Concentration:Point in time:Serum:Ordinal
Oncorhynchus mykiss antigen
Oncorhynchus mykiss ranavirus
Oncorhynchus nerka
Oncorhynchus nerka (Walbaum, 1792)
Oncorhynchus rhodurus
Oncorhynchus rhodurus Jordan & McGregor, 1925
Oncorhynchus sp.
Oncorhynchus sp. BZ-2002
Oncorhynchus sp. FY-02
Oncorhynchus sp. KD-2003
Oncorhynchus tschawytscha
Oncorhynchus tshawytscha
Oncorhynchus tshawytscha (fish)
Oncorhynchus tshawytscha (homeopathic remedy)
Oncorhynchus tshawytscha (Walbaum, 1792)
Oncorhyncin III
Oncorhyncus kisutch
Oncornaviral Protein P19
Oncornavirus
Oncornavirus, Type D
Oncornaviruses
Oncornaviruses, Type D
Oncosal
OncoScint
ONCOSCINT CR OV INJECTION 1 MG
OncoScint CR/OV
OncoScint CR103
Oncosiphon
Oncosiphon grandiflorum
Oncosiphon suffruticosum
Oncosiphon suffruticosum (L.) Kallersjo
Oncosis
Oncosperma
Oncosperma horridum
Oncosperma tigillarium
Oncosperma tigillarum
Oncospermatinae
oncostatin M
Oncostatin M [Chemical/Ingredient]
Oncostatin M Gene
Oncostatin M Leukemia Inhibitory Factor Shared Receptor
oncostatin M receptor
Oncostatin M Receptor beta
Oncostatin M Receptor beta Chain
Oncostatin M Receptor beta Subunit
Oncostatin M Receptor beta Subunit [Chemical/Ingredient]
oncostatin M receptor beta subunit, human
oncostatin M receptor beta subunit, mouse
Oncostatin M Receptor Gene
Oncostatin M Receptor wt Allele
oncostatin M receptor, human
oncostatin M receptor, mouse
Oncostatin M Receptors
oncostatin M specific receptor, rat
Oncostatin M Type I Receptor
Oncostatin M Type II Receptor
Oncostatin M wt Allele
Oncostatin M-Leukemia Inhibitory Factor Shared Receptor
ONCOSTATIN M-SPECIFIC RECEPTOR, BETA
oncostatin M, human
oncostatin M, mouse
oncostatin-M
oncostatin-M receptor activity
oncostatin-M receptor binding
oncostatin-M receptor complex
oncostatin-M receptor complex location
oncostatin-M receptor ligand
Oncostatin-M Specific Receptor Beta Subunit
Oncostatin-M Specific Receptor Subunit Beta
Oncostema
Oncostema dimartinoi
Oncostema peruviana
Oncostema villosa
Oncostemon
Oncostemons
Oncostemum
Oncostemum sp. AAA-2004
Oncostemum sp. Villiers et al. 4937
Oncostoma
Oncostoma cinereigulare
Oncostylus
Oncostylus cockaynei
Oncostylus leiospermus
oncosuppressor gene
Oncotam
Oncotheca
Oncotheca balansae
Oncothecaceae
Oncothrips
Oncothrips antennatus
Oncothrips habrus
Oncothrips morrisi
Oncothrips rodwayi
Oncothrips schwarzi
Oncothrips sterni
Oncothrips tepperi
Oncothrips torus
Oncothrips waterhousei
oncotic
Oncotic Pressure Alteration
Oncotic Pressure Alteration [PE]
Oncotice
Oncotiotepa
oncotomy
Oncotophasma
Oncotophasma martini
Oncotophasma martini (Griffini, 1896)
Oncotylus
Oncotylus Fieber, 1858
Oncotylus guttulatus
Oncotype DX
Oncotype DX Breast Cancer Assay
OncoVAX
Oncovax-ID/IL-2 Vaccine
OncoVax-Pr
OncoVEX GM-CSF
Oncovin
Oncovin 1 MG/ML Injectable Solution
Oncovin-Etoposide-Prednisone-Adriamycin Regimen
Oncovin-Etoposide-Prednisone-Adriamycin Regimen (OEPA Regimen)
Oncovin-Etoposide-Prednisone-Adriamycin/Cyclophosphamide-Oncovin-Prednisone-Procarbazine Regimen
Oncovin-Etoposide-Prednisone-Adriamycin/Cyclophosphamide-Oncovin-Prednisone-Procarbazine Regimen (OEPA-COPP Regimen)
Oncovin-Prednisone-Procarbazine-Adriamycin Regimen
Oncovin-Prednisone-Procarbazine-Adriamycin Regimen (OPPA Regimen)
Oncovin-Prednisone-Procarbazine-Adriamycin/Cyclophosphamide-Oncovin-Prednisone-Procarbazine Regimen
Oncovin-Prednisone-Procarbazine-Adriamycin/Cyclophosphamide-Oncovin-Prednisone-Procarbazine Regimen (OPPA-COPP Regimen)
Oncovin, 1 mg/mL intravenous solution
Oncovine
Oncovirinae
Oncovirus
Oncovirus, Type B
Oncovirus, Type C
Oncovirus, Type D
Oncoviruses
Oncoviruses Type B
Oncoviruses Type B, Mammalian
Oncoviruses, Type B
Oncoviruses, Type C
Oncoviruses, Type D
Oncovite
Oncovite, Multiple Vitamins oral tablet
oncrasin-1
ond(a) antigen
onda cryl
Ondanestron
Ondansetron
ondansetron (as ondansetron hydrochloride) 24 MG Oral Tablet
ondansetron (as ondansetron hydrochloride) 4 MG Oral Tablet
ondansetron (as ondansetron hydrochloride) 8 MG Oral Tablet
Ondansetron [Chemical/Ingredient]
ONDANSETRON @ 16MG @ SUPPOSITORY, RECTAL
ONDANSETRON @ 4MG @ TABLET, RAPID DISSOLVE
ONDANSETRON @ 4MG @ WAFER
ONDANSETRON @ 8MG @ TABLET, RAPID DISSOLVE
ONDANSETRON @ 8MG @ WAFER
Ondansetron 0.64 MG/ML
Ondansetron 0.64 MG/ML [Zofran]
Ondansetron 0.64 MG/ML Injectable Solution
Ondansetron 0.64 MG/ML Injectable Solution [Zofran]
ONDANSETRON 0.64MG/ML/D5W INJ BAG 50ML
Ondansetron 0.8 MG/ML
Ondansetron 0.8 MG/ML [Zofran]
Ondansetron 0.8 MG/ML Oral Solution
Ondansetron 0.8 MG/ML Oral Solution [Zofran]
Ondansetron 1 MG/ML
Ondansetron 1 MG/ML Oral Suspension
Ondansetron 16 MG
Ondansetron 16 MG [Zofran]
Ondansetron 16 MG Oral Tablet
Ondansetron 16 MG Rectal Suppository
Ondansetron 16 MG Rectal Suppository [Zofran]
ONDANSETRON 16MG SUPPOSITORY, RECTAL
ONDANSETRON 2 MG / ONDANSETRON 4 MG INTRAMUSCULAR INJECTION, SOLUTION
ONDANSETRON 2 MG / ONDANSETRON 4 MG INTRAVENOUS INJECTION, SOLUTION
ondansetron 2 mg in 1 mL INTRAMUSCULAR INJECTION [Ondansetron]
ondansetron 2 mg in 1 mL INTRAVENOUS INJECTION [Ondansetron]
ONDANSETRON 2 MG INTRAMUSCULAR INJECTION
ONDANSETRON 2 MG INTRAMUSCULAR INJECTION, SOLUTION
ONDANSETRON 2 MG INTRAVENOUS INJECTION
ONDANSETRON 2 MG INTRAVENOUS INJECTION, SOLUTION
Ondansetron 2 MG/ML
Ondansetron 2 MG/ML [Zofran]
Ondansetron 2 MG/ML Injectable Solution
Ondansetron 2 MG/ML Injectable Solution [Zofran]
Ondansetron 2.5 MG/ML
Ondansetron 2.5 MG/ML [Zofran]
Ondansetron 2.5 MG/ML Injectable Solution
Ondansetron 2.5 MG/ML Injectable Solution [Zofran]
Ondansetron 24 MG
Ondansetron 24 MG [Zofran]
Ondansetron 24 MG Oral Tablet
Ondansetron 24 MG Oral Tablet [Zofran]
Ondansetron 30 MG
Ondansetron 30 MG Oral Tablet
ONDANSETRON 32 MG INTRAVENOUS INJECTION, SOLUTION
ONDANSETRON 32 MG INTRAVENOUS INJECTION, SOLUTION [ZOFRAN]
ondansetron 32 mg/50 ml intravenous solution
ondansetron 32 mg/50 mL-D5% intravenous solution
ONDANSETRON 32 MG/50ML INTRAVENOUS INJECTION, SOLUTION
Ondansetron 4 mg
ondansetron 4 MG (ondansetron hydrochloride 5 MG) Oral Tablet
Ondansetron 4 MG [Zofran]
Ondansetron 4 MG Disintegrating Tablet
Ondansetron 4 MG Disintegrating Tablet [Zofran]
ONDANSETRON 4 MG INTRAMUSCULAR INJECTION
ONDANSETRON 4 MG INTRAMUSCULAR INJECTION, SOLUTION
ONDANSETRON 4 MG INTRAVENOUS INJECTION
ONDANSETRON 4 MG INTRAVENOUS INJECTION, SOLUTION
ONDANSETRON 4 MG Oral (systemic) disintegrating tablet
ONDANSETRON 4 MG ORAL SOLUTION
ONDANSETRON 4 MG ORAL TABLET
Ondansetron 4 MG Oral Tablet [Zofran]
ondansetron 4 mg oral tablet, disintegrating
ONDANSETRON 4 mg ORAL TABLET, ORALLY DISINTEGRATING
ONDANSETRON 4 MG ORAL TABLET, ORALLY DISINTEGRATING [ZOFRAN]
ONDANSETRON 4 MG ORAL TABLET, SOLUBLE
ondansetron 4 MG per 5 ML Oral Solution
ONDANSETRON 4 MG/2ML INTRAMUSCULAR INJECTION, SOLUTION
ONDANSETRON 4 MG/2ML INTRAVENOUS INJECTION, SOLUTION
ondansetron 4 mg/5 mL oral solution
Ondansetron 4 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING
ondansetron 4 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING [Ondansetron]
ondansetron 4 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING [ZOFRAN]
ONDANSETRON 40 MG INTRAMUSCULAR INJECTION
ONDANSETRON 40 MG INTRAVENOUS INJECTION
ONDANSETRON 4MG ORAL DISINTEGRATING TAB
Ondansetron 4mg Oral dissolving tablet
ONDANSETRON 4MG ORAL TABLET, DISPERSIBLE LINGUAL
ONDANSETRON 4MG ORAL TABLET, RAPID DISSOLVE
ONDANSETRON 4MG TABLET, RAPID DISSOLVE
ONDANSETRON 4MG WAFER
Ondansetron 8 MG
ondansetron 8 MG (ondansetron hydrochloride 10 MG) Oral Tablet
Ondansetron 8 MG [Zofran]
ONDANSETRON 8 MG / ONDANSETRON HYDROCHLORIDE 8 MG ORAL TABLET
ONDANSETRON 8 MG / ONDANSETRON HYDROCHLORIDE 8 MG ORAL TABLET [ZOFRAN]
ONDANSETRON 8 MG / ONDANSETRON HYDROCHLORIDE 8 MG ORAL TABLET, COATED [ZOFRAN]
ONDANSETRON 8 MG / ONDANSETRON HYDROCHLORIDE 8 MG ORAL TABLET, FILM COATED [ZOFRAN]
Ondansetron 8 MG Disintegrating Tablet
Ondansetron 8 MG Disintegrating Tablet [Zofran]
ONDANSETRON 8 MG Oral (systemic) disintegrating tablet
Ondansetron 8 MG Oral Tablet
ONDANSETRON 8 MG ORAL TABLET [ITMD]
ONDANSETRON 8 MG ORAL TABLET [ONDANSETRO]
Ondansetron 8 MG Oral Tablet [Zofran]
ondansetron 8 mg oral tablet, disintegrating
ONDANSETRON 8 MG ORAL TABLET, FILM COATED
ONDANSETRON 8 MG ORAL TABLET, FILM COATED [ZOFRAN]
ONDANSETRON 8 mg ORAL TABLET, ORALLY DISINTEGRATING
ONDANSETRON 8 MG ORAL TABLET, ORALLY DISINTEGRATING [ZOFRAN]
ONDANSETRON 8 MG ORAL TABLET, SOLUBLE
ONDANSETRON 8 MG ORAL TABLET, SOLUBLE [ONDASETRON]
Ondansetron 8 MG/ML
Ondansetron 8 MG/ML Injectable Solution
Ondansetron 8 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING
ondansetron 8 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING [Ondansetron]
ondansetron 8 MILLIGRAM In 1 TABLET ORAL TABLET, ORALLY DISINTEGRATING [ZOFRAN]
ONDANSETRON 8MG ORAL DISINTEGRATING TAB
Ondansetron 8mg Oral dissolving tablet
ONDANSETRON 8MG ORAL TABLET, DISPERSIBLE LINGUAL
ONDANSETRON 8MG ORAL TABLET, RAPID DISSOLVE
ONDANSETRON 8MG TABLET, RAPID DISSOLVE
ONDANSETRON 8MG WAFER
ONDANSETRON AND DEXTROSE INJECTION 32 MG/50ML
Ondansetron Disintegrating Tablet
Ondansetron Disintegrating Tablet [Zofran]
ONDANSETRON HCL @ 16MG @ SUPPOSITORY, RECTAL
ONDANSETRON HCL @ 24MG @ TABLET
ONDANSETRON HCL @ 2MG/ML @ AMPUL (ML)
ONDANSETRON HCL @ 2MG/ML @ VIAL (SDV,MDV OR ADDITIVE) (ML)
ONDANSETRON HCL @ 4MG @ TABLET
ONDANSETRON HCL @ 4MG/5ML @ SOLUTION, ORAL
ONDANSETRON HCL @ 5MG/5ML @ SUSPENSION, ORAL (FINAL DOSE FORM)
ONDANSETRON HCL @ 8MG @ TABLET
ONDANSETRON HCL 0.64MG/ML/DEXTROSE 5% INJ,BAG,50ML
ONDANSETRON HCL 0.64MG/ML/DEXTROSE 5% INJ,BAG,50ML [VA Product]
ONDANSETRON HCL 16MG SUPPOSITORY, RECTAL
ONDANSETRON HCL 2 mg/mL INTRAVEN. VIAL (SDV,MDV OR ADDITIVE) (ML)
ONDANSETRON HCL 24MG ORAL TABLET
ONDANSETRON HCL 24MG TAB
ONDANSETRON HCL 24MG TAB [VA Product]
ONDANSETRON HCL 24MG TABLET
ONDANSETRON HCL 2MG/ML AMPUL (ML)
ONDANSETRON HCL 2MG/ML INJ,SOLN
ONDANSETRON HCL 2MG/ML INJ,SOLN [VA Product]
ONDANSETRON HCL 2MG/ML INTRAVEN. VIAL (SDV,MDV OR ADDITIVE) (ML)
ONDANSETRON HCL 2MG/ML INTRAVENOUS VIAL (SDV,MDV OR ADDITIVE) (ML)
ONDANSETRON HCL 2MG/ML VIAL (SDV,MDV OR ADDITIVE) (ML)
ONDANSETRON HCL 4MG ORAL TABLET
ONDANSETRON HCL 4MG TAB
ONDANSETRON HCL 4MG TAB [VA Product]
ONDANSETRON HCL 4MG TAB,ORALLY DISINTEGRATING
ONDANSETRON HCL 4MG TAB,ORALLY DISINTEGRATING [VA Product]
ONDANSETRON HCL 4MG TABLET
ONDANSETRON HCL 4MG/5ML ORAL SOLN
48 49 50 51 52